Cetera Investment Advisers
KRYS icon

Cetera Investment Advisers’s Krystal Biotech KRYS Stock Holding History

Cetera Investment Advisers’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.6M Buy
6,206
+1,590
+34% +$423K ﹤0.01% 2486
2025
Q4 		$1.14M Buy
4,616
+118
+3% +$24.8K ﹤0.01% 2710
2025
Q3 		$794K Buy
4,498
+154
+4% +$23.1K ﹤0.01% 2987
2025
Q2 		$597K Buy
4,344
+2,255
+108% +$331K ﹤0.01% 2823
2025
Q1 		$377K Sell
2,089
-87
-4% -$14.6K ﹤0.01% 3083
2024
Q4 		$341K Buy
2,176
+31
+1% +$5.5K ﹤0.01% 3001
2024
Q3 		$390K Buy
2,145
+561
+35% +$108K ﹤0.01% 2859
2024
Q2 		$291K Buy
1,584
+449
+40% +$75.4K ﹤0.01% 3056
2024
Q1 		$202K Buy
+1,135
New +$158K ﹤0.01% 3343

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cetera Investment Advisers's KRYS Position: Q1 2026 in Review

Cetera Investment Advisers increased its Krystal Biotech (KRYS) stake by 34% in Q1 2026, buying an estimated $423K and bringing the position to 6,206 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2486.

Cetera Investment Advisers first reported a position in KRYS in Q1 2024 and has held it in 9 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Cetera Investment Advisers held 6,206 shares of Krystal Biotech worth $1.6M as of Q1 2026.
  • Cetera Investment Advisers bought 1,590 Krystal Biotech shares in Q1 2026, an estimated $423K.
  • Krystal Biotech made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #2486 holding.
  • Cetera Investment Advisers first reported a position in Krystal Biotech in Q1 2024 and has held it in 9 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.